- The Washington Times - Wednesday, June 22, 2005


People are most at risk of dropping dead in the first month after a heart attack, a study finds, but the most effective treatment for prevention isn’t performed that early because it, too, is considered riskiest during that period.

The research could encourage doctors to rethink how patients are treated in those crucial early days.

The rate of sudden death was 10 times higher in the first month after a heart attack compared with two years later, researchers report in today’s New England Journal of Medicine.

“We need to consider therapies and strategies … that could protect patients during this early vulnerable period following a heart attack,” said Dr. Scott Solomon, a cardiologist at Brigham and Women’s Hospital in Boston, who led the study.

Most heart attacks are caused by blockages that deprive the pumping muscle of blood and oxygen. Treatments can clear these and restore blood flow, but damage from the heart attack can lead to abnormal rhythms that can stop the heart without warning.

The problem is becoming more common as heart attack treatment improves. Sudden death now accounts for two out of three heart deaths in the United States, about 450,000 cases each year.

Studies have shown that implanted defibrillators — like the one Vice President Dick Cheney has — can help prevent sudden death by shocking the heart back into a normal rhythm. But those studies were conducted in patients several years after a heart attack.

Last year, a study in the same journal reported that putting the pager-size devices in people just weeks after a heart attack does not improve survival, and guidelines by the American College of Cardiology and American Heart Association recommend that doctors wait one to three months before implanting the device.

The new study shows the dilemma that creates. “This study shows that patients right after a heart attack perhaps have the highest risk of sudden cardiac death and those patients are deprived of getting a defibrillator. It’s an area that we need to study more closely,” said heart association spokesman Dr. Kenneth Ellenbogen, a professor at Medical College of Virginia who was not connected with the study.

Researchers studied 14,609 patients enrolled in a drug trial who had suffered a muscle-damaging heart attack or heart failure between 1998 and 2001. Seven percent either died suddenly or were revived after cardiac arrest.

The study was funded by Novartis Pharmaceuticals, which makes several cholesterol and blood pressure-lowering drugs.

Copyright © 2019 The Washington Times, LLC. Click here for reprint permission.

The Washington Times Comment Policy

The Washington Times welcomes your comments on Spot.im, our third-party provider. Please read our Comment Policy before commenting.


Click to Read More and View Comments

Click to Hide